FluoGuide筹集了104M瑞典克朗的股份销售,以资助癌症试验发展和执行奖励。 FluoGuide raised SEK 104M in a share sale to fund cancer trial development and executive incentives.

2025年11月3日,FluoGuide A/S向包括主要股东在内的北欧机构投资者发行了270万股,每股38瑞典克朗,占最后价格的95%。 FluoGuide A/S raised SEK 104 million in a directed share issue on November 3, 2025, issuing 2.7 million shares at SEK 38 each, 95% of the closing price, to Nordic institutional investors including major shareholders. 这笔收入将用于对古洛马和头颈癌的FG001 FG001进行第二阶段试验,CMC为第三阶段试验和一般业务工作提供资金。 The proceeds will fund phase II trials for FG001 in glioma and head and neck cancer, CMC work for a phase III trial, and general operations. 该公司还向高管和董事会成员发放了199000个股票券,价格为38瑞典克朗,拥有三年的资产权限期,并行使权限至2035年,旨在调整长期激励措施. The company also granted 199,000 warrants to executives and board members at SEK 38, with a three-year vesting period and exercise rights until 2035, aiming to align long-term incentives. Nasdaq第一北增长市场股票将于11月14日前公布。 Shares will list on Nasdaq First North Growth Market by November 14. 资本的增加增加了股本资本,导致16.69%的稀释。 The capital increase raises share capital and results in a 16.69% dilution. 对新发单实行90天封锁,对支持投资者信心的管理人员实行180天销售禁令。 A 90-day lock-up on new issuances and 180-day sales ban for executives support investor confidence. 信贷机制仍然为4 000万瑞典克朗,延长至2027年4月。 The credit facility remains at SEK 40 million, extended to April 2027.